ABSTRACT
Neuroendocrine tumors (NETs) are one of the rare cancers that have been increasing in recent years. The importance of Ga-68 DOTA-Conjugated Peptides Receptor imaging has been reported in many retrospective and prospective studies in the diagnosis and clinical management of NETs. Three different somatostatin analogues labeled Ga-68 are used in clinical practice. The most commonly used Ga-68 DOTA-Conjugated Peptides are DOTA-D-Phe-Tyr3-octreotide (DOTA-TOC), DOTA-1-NaI (3)- octreotide (DOTA-NOC) and DOTA-D-Phe-Tyr3-octreotate (DOTA-TATE) in rutin. Although all these radiopeptides bind to sst-r 2, each has different affinity profiles for other sst-r subtypes. Performed related studies have shown that the compound with the highest affinity for somatostatin receptor 2 (sst-r 2), which is most frequently expressed in NETs, is DOTA-TATE. Ga-68 DOTA-bound somatostatin receptor (sst-r) PET/CT is used in the preoperative staging of NETs, determination of treatment response, restaging, showing somatostatin receptor uptake before peptide receptor radionuclide treatment. This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Ga-68 DOTA conjugated peptid PET/CT imaging in NETs.
References
1Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335-1342.
2Reubi J, Waser B, Schaer J-C, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med Mol Imaging 2001;28:836-846.
3Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 2003;24:389-427.
4Werner RA, Weich A, Kircher M, et al. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-6100.
5Aliyev A, Ocak M, Kabasakal L, et al. Intraoperative localization of recurrent medullary carcinoma of the thyroid using Tc-99m HYNIC-TATE and a surgical gamma probe. Clin Nucl Med 2011;36:831-833.
6Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518.
7Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-860.
8Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-1434.
9Sundin A, Arnold R, Baudin E, et al. ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 2017;105:212-244.
10Norlen O, Montan H, Hellman P, Stålberg P, Sundin A. Preoperative (68)Ga-DOTAsomatostatin analog-PET/CT hybrid imaging increases detection rate of intra-abdominal small Intestinal neuroendocrine tumor lesions. World J Surg 2018;42:498-505.
11Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi B-I. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 2016;26:1338-1347.
12d’Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusionweighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 2013;268:390-399.
13Ronot M, Clift AK, Baum RP, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology 2018;106:74-88.
14Chambers AJ, Pasieka JL, Dixon E, Rorstad O. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. J Am Coll Surg 2010;211:620-627.
15Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271-2277.
16Ambrosini V, Fanti S. PET/CT in Neuroendocrine Tumours. PET/CT Neuroendocr Tumors. 2016:45-53.
17Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770-1780.
18Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging 2017;44:1588-1601.
19Woltering EA, Bergsland EK, Beyer DT. Neuroendocrine Tumors of the Stomach. American Joint Committee on Cancer 2017. In: Amin MB editor. AJCC Cancer Staging Manual. Eighth Edition. Springer 2017:351-359.
20WHO Classification of Tumours Editorial Board; Digestive System Tumours, WHO Classification of Tumours. 5th ed. Lyon, France: IARC Press; 2019.
21Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37:46-48.
22Conry BG, Papathanasiou ND, Prakash V, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37:49-57.
23Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-2455.
24Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18FDOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-1438.
25Fanti S, Ambrosini V, Tomassetti P, et al. Evaluation of unusual euroendocrine tumours by means of 68Ga-DOTA-NOCPET. Biomed Pharmacother 2008;62:667-671.
26Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-1932.
27Ambrosini V, Castellucci P, Rubello D, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281-286.
28Schartinger VH, Dudás J, Decristoforo C, et al. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2013;40:1365-1372.
29National Comprehensive Cancer Network. (2019). Neuroendocrine and Adrenal Tumors (version 1.2019). Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Published 2019.
30Wannachalee T, Turcu AF, Bancos I, et al. The Clinical Impact of [68Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours. Clin Endocrinol (Oxf) 2019;91:288-294.
31Öksüz MÖ, Winter L, Pfannenberg C, et al. Peptide receptor radionuclide therapy of neuroendocrine tumorswith(90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of(68)Ga-DOTATOC? Diagn Interv Imaging 2014;95:289-300.
32Virgolini I, Ambrosini V, Bomanji JB, et al. Procedureguidelinesfor PET/CT tumourimagingwith 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-2010.
33Velikyan I, Sundin A, Eriksson B, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol 2010;37:265-275.
34Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutictumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med 2012;37:e141-147.
35Machado JS, Beykan S, Herrmann K, et al. Recommended administered activities for (68)Ga-labelled peptides in paediatric nuclear medicine. Eur J Nucl Med Mol Imaging 2016;43:2036-2039.
36Hartmann H, Zöphel K, Freudenberg R, et al. Radiation exposure of patients during 68GaDOTATOC PET/CT examinations. Nuklearmedizin 2009;48:201-207.
37Pettinato C, Sarnelli A, Di Donna M, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-79.
38Walker RC, Smith GT, Liu E, et al. Measured human dosimetry of 68 Ga-DOTATATE. J Nucl Med 2013;54:855-860.
39Hofmann M, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757.
40Kabasakal L, Demirci E, Ocak M, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:1271-1277.
41Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68GaDOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:364-272.
42Virgolini I, Gabriel M, Kroiss A, et al. Current knowledge on the sensitivity of the(68)Ga Somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2016;43:2072-2083.
43Blake MA, Singh A, Setty BN, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics 2006;26:1335-1353.
